{"name":"Whanin Pharmaceutical Company","slug":"whanin-pharmaceutical-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"INM-176","genericName":"INM-176","slug":"inm-176","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"INM-176","genericName":"INM-176","slug":"inm-176","phase":"phase_3","mechanism":"INM-176 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE82ZjhjeTZtYjFZak9kZ3FpQU5zUmw4QWUtN3BWMkxDb0U0aHMwVU43bzJJX1lOYmJ0cDFWdm5rVkFQRUJHMF82c1pyRWl5STlxdWZyY3I1dFdXbWVLbE8zMnMwaTZIeXZWODI1RS1n0gFyQVVfeXFMT1lxemhRcnJhVFhvM2doclVzTG1WY0ZVcDFTRFh3dXJZSE5iZk9OeUJxQjRDLXhxUXlrZTl0MmZZRjJPRmZjcGQ3WUdjWC1nbUdQci1wNVJUV2tnb3EzZUhqQTcxYU5GSngtcEd6M3NpTXZ3?oc=5","date":"2025-08-28","type":"pipeline","source":"koreabiomed.com","summary":"Myungin Pharm eyes schizophrenia drug candidate as growth driver ahead of IPO - koreabiomed.com","headline":"Myungin Pharm eyes schizophrenia drug candidate as growth driver ahead of IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNUGVzYm9ZQW54UDJKUmtLQUdoUkFxQ1hsc1FGaXZHRzg5Z0tFOV9wMzRTMWRjUjdrdWczLTBRMDk0d0Z6Z3VCeWlWNmdNejhzY3M3dHVXNlNWbERDR2stUFhaMkZiNTJ6ZUdlWUJtR1ExNlBTQWwtQUxJb3lDNnVNRNIBlAFBVV95cUxQUWpTQ0tnam1pVTBPUUR3TnJ6Q1pkSTRXbm43MVZLMnJKekhKV2hpRkowM1FHS3A0cnFQX2kxcm81YWNvWFlCS0paclI4em94ZmEtbVNvSXZ3VzNIUWtQVzNaZ2NmQ1hCRGVlLTQwNzZOaGN0bzNteW1OOHU1TGhjb3M5N01zanlNLS1WZW1KWGJscG5z?oc=5","date":"2025-03-27","type":"trial","source":"Chosunbiz","summary":"[Gwanghwamun pharmacy] Study-Boosting Pills Sweep Korea’s Cram School Hub, Raising Concerns Over Impulsivity and Violence in Non-ADHD Users - CHOSUNBIZ - Chosunbiz","headline":"[Gwanghwamun pharmacy] Study-Boosting Pills Sweep Korea’s Cram School Hub, Raising Concerns Over Impulsivity and Violenc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1tY1ptSUhqSVh4Rm1oTl9EY29obVJOcGRDY2laQ0lVNnd5ck1kX05sendDN1pjZ0ZVam1jOW5Ea2lBaDJCREpfcmNlUWtibWRZaTBVRkZFV0ZVaWZ6dlIwdXhIdVl4MTBuNENIa3Vn0gFyQVVfeXFMTzhVU05vcW9zalQyZk5xMzl5OV9ITVg3X1NFc0NmMXJmZF8tei0xN2Y3MWlQRHNNUktsNEZLM054TjhDU2Z4Uk1iWm9yamE1WXJfM2FDWGp2dEp2RHBzeHJsc1V2TDFvWE00dkNTNWlaZi1B?oc=5","date":"2024-06-27","type":"regulatory","source":"koreabiomed.com","summary":"Nicergoline-based brain enhancers get regulatory nods - koreabiomed.com","headline":"Nicergoline-based brain enhancers get regulatory nods","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5uVjkzN2lRUEc2ZG92c1pGTXBfUk9VeThCOXJCQkVKcWFpZWVjNUE5b3JlR2RScjljRng0QU54SHByU2JmSzJaQ0xsOFJQUjh6M1J2WFM2MmFCOXdfVTRDUVBTMEh1TG5yWlloc2x30gFyQVVfeXFMTW0wclJmZVhRN3BSU1BmYm42VTZINUJBZ3pyVzlnc1RHaEVjM2RpZkRJaGFKRjJKQnJSVDY4dmh0MGxJVkppbGR0RW5EQURySEV0VEpOWnNLNmpab3htXzRHR2JrOFFvaFE0RU94MEh2RmtB?oc=5","date":"2022-03-22","type":"pipeline","source":"koreabiomed.com","summary":"Janssen discontinues drug manufacturing in Korea - koreabiomed.com","headline":"Janssen discontinues drug manufacturing in Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNNkNuOVJSN2E2UWZ5SzJJTV9WY082M0h4UG1HV2RscDVDTHJpMU4xZ0x3NEFORkFOQW1ObkM4WkFlUkZlYkFLVThSdERSRWktQnFQRHBVV3o0VXJOUEh1Y2kzRTJ2bzBLc3FMclRtNjhFWG5aVXQ0Y1lxRjE2ZXd2bDZqUFAyLXhuajFFQw?oc=5","date":"2018-02-27","type":"deal","source":"The Pharma Letter","summary":"BIAL out-licenses Zebinix in South Korea - The Pharma Letter","headline":"BIAL out-licenses Zebinix in South Korea","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}